肿瘤细胞治疗研究
英文原题：Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.
化疗仍是晚期 EAC/GEJAC 治疗的基石。
综述目的：本文重点介绍晚期食管腺癌（EAC）和胃食管结合部腺癌（GEJAC）治疗模式的进展和近期变化。近期发现：化疗仍是晚期 EAC/GEJAC 治疗的基础。新靶点/药物包括免疫疗法、HER2、claudin18.2 和 FGFR2b；针对这些靶点的不同机制治疗（CAR-T、双特异性单克隆抗体和抗体药物偶联物 [ADC]）正在改变治疗格局。这些靶向方法可联合、序贯，甚至产生协同作用，从而改善结局。本文综述该领域现状，包括正在开展的临床试验及其他新兴药物和治疗方法。
PURPOSE OF REVIEW: This review highlights advances and recent changes in the treatment paradigm for advanced esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC). RECENT FINDINGS: Chemotherapy remains the backbone of treatment for advanced EAC/GEJAC. New targets/agents include immunotherapy, HER-2, claudin18.2, and FGFR2b, with various mechanisms (CAR-T, bispecific mAB, ADCs) altering the treatment landscape against these targets. The approaches to these targets may act together, in sequence, and even synergistically to improve outcomes. Herein, we review the state of the field, including highlighting ongoing clinical trials and additional emerging agents and approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。
